Introduction {#tca12428-sec-0005}
============

Lung cancer remains the leading cause of death among all cancers, and a relationship between tumor node metastasis (TNM) stage and survival has been reported.[1](#tca12428-bib-0001){ref-type="ref"} Over the past decade, the overall survival (OS) of lung cancer patients has greatly improved.[2](#tca12428-bib-0002){ref-type="ref"} This progress is largely a result of the introduction of new drugs and individualized therapy based on different histological subtypes and driver mutations that determine the biology of lung cancers and can be used to predict drug efficacy.[3](#tca12428-bib-0003){ref-type="ref"} The epidermal growth factor receptor (*EGFR*) gene is currently the most promising and "druggable" oncogene in non‐small cell lung cancer (NSCLC). The targeting of *EGFR*s, especially by using *EGFR*‐tyrosine kinase inhibitors (TKIs), has played a central role in advancing NSCLC research, treatment, and outcome prediction. Recently, *EGFR*‐TKIs have also been shown to improve OS in certain *EGFR* mutations.[4](#tca12428-bib-0004){ref-type="ref"} Some specific *EGFR* mutations are associated with sensitivity to *EGFR*‐TKIs. Small exon 19 deletion (del 19) and exon 21‐point mutation (L858R) are the two most common mutations associated with improved outcomes after *EGFR*‐TKI therapy.[5](#tca12428-bib-0005){ref-type="ref"}, [6](#tca12428-bib-0006){ref-type="ref"}, [7](#tca12428-bib-0007){ref-type="ref"} K‐*ras* is another oncogene, in which mutations occur more frequently in smokers. Compared with an approximate 50% mutation rate of the gene encoding *EGFR* in Asian patients, the mutation rate of *EGFR* is only 10--15% in white populations.[8](#tca12428-bib-0008){ref-type="ref"} ^,^ [9](#tca12428-bib-0009){ref-type="ref"} K‐*ras* is the most commonly mutated oncogene in lung cancers in Western countries, with activating point mutations in 15--20% of all NSCLCs[10](#tca12428-bib-0010){ref-type="ref"}, [11](#tca12428-bib-0011){ref-type="ref"} and 25--35% of all adenocarcinomas.[12](#tca12428-bib-0012){ref-type="ref"}, [13](#tca12428-bib-0013){ref-type="ref"} Many studies have suggested that mutated K‐*ras* is associated with poorer OS in patients with NSCLC.[14](#tca12428-bib-0014){ref-type="ref"} Anti‐*EGFR* therapies are ineffective for K‐*ras* mutant tumors, which are associated with a lack of sensitivity and poorer clinical outcomes when treated with *EGFR*‐TKIs or chemotherapy.[15](#tca12428-bib-0015){ref-type="ref"}, [16](#tca12428-bib-0016){ref-type="ref"}, [17](#tca12428-bib-0017){ref-type="ref"} It is worth noting that *EGFR* and K‐*ras* mutations are rarely found in the same tumor, suggesting that they may drive functionally different carcinogenetic processes. Direct targeting of K‐*ras* has recently raised some concern, as this represents a key transduction pathway in both normal and tumor tissues. Moreover, several parallel escape mechanisms have been identified.[18](#tca12428-bib-0018){ref-type="ref"} Moving from these considerations, alternative targeting of K‐*ras* is currently under evaluation.

The aims of the present study were to evaluate mutations of the *EGFR* and K‐*ras* genes at the time of surgery and to analyze the clinical significance of these mutations in terms of their prognostic and predictive value in pathological stage I adenocarcinoma patients.

Methods {#tca12428-sec-0006}
=======

Patient eligibility {#tca12428-sec-0007}
-------------------

Between April 2007 and December 2013, 332 consecutive patients underwent pulmonary resection for lung cancer at the Sagamihara Kyodo Hospital, Kanagawa, Japan. We reviewed the data of 162 of these patients who were diagnosed with pathological stage I adenocarcinoma according to the seventh edition of the TNM Staging Classification for Lung Cancer. Patients who underwent incomplete resection or neoadjuvant chemotherapy/radiotherapy were excluded.

We reviewed the medical records of each patient for the following clinicopathological information: age, gender, smoking habit, serum carcinoembryonic antigen (CEA), extent of pulmonary resection, tumor location, maximum standardized uptake value (SUV~max~) of the primary tumor, tumor size (cm), grade, pleural invasion, mucinous components, *EGFR* mutation status, K‐*ras* mutation status, and pathological stage. All clinical, intraoperative, radiological, and pathological findings from two hospitals in Kanagawa, Japan (Sagamihara Kyodo Hospital and Yuai Clinic) were reviewed. The patients' characteristics and preoperative and postoperative tumor evaluations are shown in Table [1](#tca12428-tbl-0001){ref-type="table-wrap"}. Histological classification of NSCLC was based on the World Health Organization classification.[19](#tca12428-bib-0019){ref-type="ref"} Preoperative and postoperative staging were based on the TNM staging system.[20](#tca12428-bib-0020){ref-type="ref"} Data collection and analyses were approved, and the need to obtain written informed consent from each patient was waived by the first author\'s institutional review board.

###### 

Clinicopathological characteristics of 162 patients with pathological stage I lung adenocarcinoma

  Variables                        N (%) or mean ± SD
  ------------------------------- --------------------
  Age at operation (year)              68.9 ± 9.7
  Gender                          
  Female                               79 (48.8%)
  Male                                 83 (51.2%)
  Smoking habit                   
  Never smoker                         82 (50.6%)
  Ever smoker                          80 (49.4%)
  Serum CEA (ng/mL)               
  ≤5                                  128 (70.0%)
  \>5                                  34 (30.0%)
  Extent of pulmonary resection   
  Sublobar resection                   51 (31.5%)
  Lobectomy or more                   111 (68.5%)
  Tumor location                  
  Central                               8 (4.9%)
  Non‐central                         154 (95.1%)
  SUV~max~ of primary tumor            3.2 ± 2.8
  Tumor size (cm)                      2.7 ± 1.7
  Grade                           
  1                                   121 (74.7%)
  2--4                                 41 (25.3%)
  Pleural invasion                
  Absent                              145 (89.5%)
  Present                              17 (10.5%)
  Mucinous components             
  Absent                              138 (85.2%)
  Present                              24 (14.8%)
  *EGFR* mutation                 
  Absent                               81 (50.0%)
  Present (exon 19)                    41 (25.3%)
  Present (exon 21)                    40 (24.7%)
  K‐*ras* mutation                
  Absent                              145 (89.5%)
  Present (codon 12)                   17 (10.5%)
  Present (codon 13)                    0 (0.0%)
  Pathological stage              
  Stage IA                            103 (63.6%)
  Stage IB                             59 (36.4%)

CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; SD, standard deviation; SUV~max~, maximum standardized uptake value.

Computed tomography {#tca12428-sec-0008}
-------------------

Diagnostic quality contrast‐enhanced computed tomography (CT) of the chest with a slice thickness of 5 mm was performed for all patients. A tumor was deemed central if its center was located in the inner one‐third of the lung parenchyma (adjacent to the mediastinum) on transverse CT. Peripherally located tumors were identified as those centered in the outer two‐thirds of the lung parenchyma on transverse CT. The maximal diameter of the lung nodules was measured on contrast‐enhanced chest CT. All imaging was performed within four weeks of surgery.

Integrated ^18^ F‐fluorodeoxyglucose positron emission tomography imaging {#tca12428-sec-0009}
-------------------------------------------------------------------------

Each patient underwent integrated ^18^F‐fluorodeoxyglucose positron emission tomography/CT (FDG‐PET/CT) imaging before surgical resection. All integrated FDG‐PET/CT imaging was performed within four weeks of surgery. After fasting for six hours, FDG (3.5 MBq/kg body weight) was intravenously injected if the patient\'s blood sugar level was lower than 200 mg/dL. Image acquisition commenced 60 minutes after the injection using a single PET/CT combined scanner (Eminence‐SOPHIA; Shimadzu, Kyoto, Japan).[21](#tca12428-bib-0021){ref-type="ref"} Image emission data from the eyes to the mid‐thigh area were continuously acquired over a period of approximately 20 minutes. After attenuation corrections were made for the resulting image data, reconstruction was performed using a dynamic row‐action expectation maximization algorithm.[22](#tca12428-bib-0022){ref-type="ref"} The reconstructed sectional images were then evaluated both visually and quantitatively using the SUV~max~ inside a volume of interest (VOI) placed on the lesions. The SUV~max~ was calculated as follows: (\[maximum activity in VOI\] / \[volume of VOI\]) / (\[injected FDG dose\] / \[patient weight\]). The quality of radiation measurements of the PET/CT scanner was assured by calibration in accordance with National Electrical Manufacturers Association NU‐2 2001 standards.[23](#tca12428-bib-0023){ref-type="ref"}

Nodal uptake with an SUV~max~ \> 2.5 was considered positive. To determine the SUV, a cylindrical region of interest (ROI) was placed over the tumor site manually on the hottest transaxial slice. The activity concentration within the ROI was determined and expressed as the SUV, where SUV is the ratio of the activity in the tissue to the decay‐corrected activity injected into the patient. All SUV measurements were normalized for patient body weight. SUV~max~ within an ROI was used as the reference measurement.[24](#tca12428-bib-0024){ref-type="ref"}

Three experienced radiologists individually analyzed the integrated FDG‐PET/CT images. Final assessment was made by consensus if the initial assessments differed.

Surgical resection {#tca12428-sec-0010}
------------------

All patients underwent anatomical lung resection and radical lymphadenectomy or sublobar resection in our hospital. Thoracic surgeons at Sagamihara Kyodo Hospital performed all surgical resections and all techniques were standardized. Systematic lymph node dissection was performed in all patients according to American Thoracic Society criteria, removing at least three hilar and three mediastinal stations.

Pathological examination {#tca12428-sec-0011}
------------------------

Experienced pulmonary pathologists examined all resected tumor specimens. Histological classification of NSCLC was based on the World Health Organization classification. Dissected lymph nodes were histologically examined following hematoxylin and eosin staining.

Epidermal growth factor receptor (EGFR) and K‐ras mutation analysis {#tca12428-sec-0012}
-------------------------------------------------------------------

Genomic DNA was extracted and purified from tumors embedded in paraffin blocks using the Takara DEXPAT kit (Takara Bio Inc., Kusatsu, Shiga, Japan) from materials macro‐dissected from the paraffin‐embedded sections. Quantification of the extracted nucleic acids and measurement of the A260/A280 ratio were performed using an ultraviolet spectrophotometer (Beckman Coulter DU800, Koto‐ku, Tokyo, Japan). A common fragment analysis was used for screening to detect the deletion in exon 19 of the *EGFR* gene. Sample DNA was amplified with a FAM‐labeled primer set: 5′‐TGGCACCATCTCACAATTGC‐3′ (forward) and 5′‐AGGATGTGGAGATGAGCAGG‐3′ (reverse). PCR products were separated by electrophoresis using an ABI PRISM 310 (Thermo Fisher Scientific, Yokohama, Kanagawa, Japan). When a deletion mutation was present, PCR was used to amplify the shorter DNA segment, thereby creating a new peak in the electropherogram. The deletion in exon 19 was confirmed using primers constructed to make a 147 bp product when the allele was wild type. The primer sequences were 5′‐TGGCACCATC TCACAATTGC‐3′ (forward) and 5′‐GAAAAGGTGGG CCTGAGGTTC‐3′ (reverse). PCR was carried out in 25 mL reaction mixtures containing 1 mL of genomic DNA using Taq DNA polymerase (Takara Bio Inc.) for 35 cycles at 64°C for annealing. To detect L858R in exon 21, a PCR assay was performed for 35 cycles at an annealing temperature of 60°C using Takara Ex‐Taq (Takara Bio Inc.). The sequencing primer was 5′‐CATGAACTACTTGGAGGACC‐3′ (forward) and 5′‐CAGGAAAATGCTGGCTGACC‐3′ (reverse). A PCR‐based restriction fragment length polymorphism analysis was performed to detect the K‐*ras* mutations in codons 12 and 13. All direct sequencing was performed to detect K‐*ras* (codons 12 and 13) mutations according to the manufacturer\'s protocol for the BigDye v1.1 kit (Applied Biosystems, Foster City, CA, USA). Sequencing was performed using the 310 Genetic Analyzer (Applied Biosystems).

Statistical analysis {#tca12428-sec-0013}
--------------------

Statistical analysis was performed using SPSS version 23.0 (IBM Corporation, Armonk, NY, USA). Survival curves were constructed using the Kaplan--Meier method. Recurrence‐free survival (RFS) probabilities and OS rates were compared using the log‐rank test. The Cox proportional hazard model was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for the univariate and multivariate analyses. All tests were two‐sided, and *P* values \<0.05 were considered statistically significant. Factors found to be significant in univariate analysis (*P* \< 0.05) were included in multivariate analysis.

Results {#tca12428-sec-0014}
=======

Patient characteristics {#tca12428-sec-0015}
-----------------------

The clinicopathological features of the 162 patients (79 women, 83 men; mean age, 68.9 years; age range 40--86 years) are listed in Table [1](#tca12428-tbl-0001){ref-type="table-wrap"}. Eighty‐two of the patients were never smokers. The median tumor size was 2.7 cm, and the median SUV~max~ of the primary tumor was 2.3. *EGFR* and K‐*ras* mutations were detected in 81 (50.0%) and 17 (10.5%) of 162 tumors, respectively. Forty‐one patients with *EGFR* gene mutations showed an exon 19 deletion, and 40 showed an exon 21‐point mutation. Seventeen patients with K‐*ras* gene mutations showed a codon 12‐point mutation, while no patients showed a codon 13‐point mutation. The *EGFR* and K‐*ras* gene mutations were mutually exclusive.

Correlations between the mutations and clinicopathological features were analyzed (Table [2](#tca12428-tbl-0002){ref-type="table-wrap"}). *EGFR* mutations were significantly associated with female gender, smoking habit (never smoker), and low grade. By contrast, K‐*ras* mutations were significantly associated with male gender, smoking habit (ever smoker), and the presence of mucinous components.

###### 

Association between mutation status and clinicopathological characteristics in patients with pathological stage I lung adenocarcinoma

  Variables                       *EGFR*(*n* = 81) N (%)   K‐*ras* (*n* = 17) N (%)   Wild (*n* = 64) N (%)   *P*
  ------------------------------- ------------------------ -------------------------- ----------------------- ---------
  Age at operation (year)                                                                                     
  \<70                            39 (48.1%)               8 (47.0%)                  30 (46.9%)              0.988
  ≥70                             42 (51.9%)               9 (53.0%)                  34 (53.1%)              
  Gender                                                                                                      
  Female                          56 (69.1%)               5 (29.4%)                  22 (34.3%)              \<0.001
  Male                            25 (30.9%)               12 (70.6%)                 42 (65.7%)              
  Smoking habit                                                                                               
  Never smoker                    54 (66.7%)               5 (29.4%)                  21 (32.8%)              \<0.001
  Ever smoker                     27 (33.3%)               12 (70.6%)                 43 (67.2%)              
  Serum CEA (ng/mL)                                                                                           
  ≤5                              69 (85.2%)               15 (88.2%)                 44 (68.8%)              0.033
  \>5                             12 (14.8%)               2 (11.8%)                  20 (31.2%)              
  Extent of pulmonary resection                                                                               
  Sublobar resection              26 (32.1%)               4 (23.5%)                  21 (32.8%)              0.754
  Lobectomy or more               55 (67.9%)               13 (76.5%)                 43 (67.2%)              
  Tumor location                                                                                              
  Central                         4 (4.9%)                 0 (0.0%)                   4 (6.2%)                0.572
  Non‐central                     77 (95.1%)               17 (100.0%)                60 (93.8%)              
  SUV~max~ of primary tumor                                                                                   
  ≤2.3                            46 (56.8%)               12 (70.6%)                 24 (37.5%)              0.015
  \>2.3                           35 (43.2%)               5 (29.4%)                  40 (62.5%)              
  Tumor size (cm)                                                                                             
  ≤3                              59 (72.8%)               14 (82.4%)                 42 (65.7%)              0.351
  \>3                             22 (27.2%)               3 (17.6%)                  22 (34.3%)              
  Grade                                                                                                       
  1                               72 (88.9%)               12 (70.6%)                 37 (57.8%)              \<0.001
  2--4                            9 (11.1%)                5 (29.4%)                  27 (42.2%)              
  Pleural invasion                                                                                            
  Absent                          74 (91.4%)               17 (100.0%)                54 (84.4%)              0.130
  Present                         7 (8.6%)                 0 (0.0%)                   10 (15.6%)              
  Mucinous components                                                                                         
  Absent                          74 (91.4%)               5 (29.4%)                  59 (92.2%)              \<0.001
  Present                         7 (8.6%)                 12 (70.6%)                 5 (7.8%)                
  Pathological stage                                                                                          
  Stage IA                        55 (67.9%)               14 (82.4%)                 34 (53.1%)              0.044
  Stage IB                        26 (32.1%)               3 (17.6%)                  30 (46.9%)              

CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; SUV~max~, maximum standardized uptake value.

Survival analysis of patients with pathological stage I adenocarcinoma after surgical resection {#tca12428-sec-0016}
-----------------------------------------------------------------------------------------------

Among the 162 patients, five‐year RFS and OS were 79.6% and 81.3%, respectively. In the survival analyses, the five‐year RFS rates were 77.8% vs. 87.8% vs. 79.2% for patients with an *EGFR* mutation, K‐*ras* mutation, and wild‐type status, respectively (Fig [1](#tca12428-fig-0001){ref-type="fig"}a). The five‐year OS rates were 82.8 vs. 82.4 vs. 79.2 for patients with an *EGFR* mutation, K‐*ras* mutation, and wild‐type status, respectively (Fig [1](#tca12428-fig-0001){ref-type="fig"}b). Significant differences were observed in both RFS and OS between patients with an *EGFR* mutation and those with wild‐type genes (RFS *P* = 0.903, OS *P* = 0.883), and between patients with an *EGFR* mutation and those with a K‐*ras* mutation (RFS *P* = 0.317, OS *P* = 0.952).

![(**a**) Recurrence‐free survival curves of pathological stage I patients after pulmonary resection. Data are shown for patients with epidermal growth factor receptor (EGFR) and K‐ras mutations and for those who were wild type for both genes. (**b**) Overall survival curves of pathological stage I patients with EGFR and K‐ras mutations or both wild‐type genes after pulmonary resection.](TCA-8-229-g001){#tca12428-fig-0001}

Univariate analysis showed that serum CEA, SUV~max~ of the tumor, pleural invasion, and pathological stage were significant unfavorable prognostic factors for RFS (*P* \< 0.05), and that age at operation, serum CEA, and SUV~max~ of the tumor were significant unfavorable prognostic factors for OS (*P* \< 0.3). In multivariate analysis adjusted for the significant univariate factors, SUV~max~ of the tumor remained an independent prognostic factor for RFS (*P* = 0.001), and age at operation and SUV~max~ of the tumor remained independent prognostic factors for OS (*P* = 0.029, 0.008; Table [4](#tca12428-tbl-0004){ref-type="table-wrap"}). *EGFR* and K‐*ras* mutations did not affect the prognosis of patients with pathological stage I adenocarcinoma.

###### 

Univariate analyses for RFS and OS in patients with pathological stage I adenocarcinoma

  Variables                       RFS                     OS                         
  ------------------------------- -------------------- --------- ------------------- -------
  Age at operation (year)                                                            
  \<70                            1                              1                   
  ≥70                             1.11 (0.57--2.15)      0.767   2.33 (1.06--5.09)    0.034
  Gender                                                                             
  Female                          1                              1                   
  Male                            1.16 (0.59--2.25)      0.666   1.03 (0.72--1.48)    0.871
  Smoking habit                                                                      
  Never smoker                    1                              1                   
  Ever smoker                     1.20 (0.86--1.68)      0.278   1.25 (0.87--1.81)    0.224
  Serum CEA (ng/mL)                                                                  
  ≤ 5                             1                              1                   
  \> 5                            2.04 (1.01--4.17)      0.049   2.61 (1.24--5.48)    0.012
  Extent of pulmonary resection                                                      
  Sublobar resection              1                              1                   
  Lobectomy or more               0.78 (0.53--1.16)      0.227   0.79 (0.52--1.21)    0.289
  Tumor location                                                                     
  Central                         1                              1                   
  Non‐central                     0.93 (0.45--1.89)      0.833   0.57 (0.78--4.21)    0.584
  SUV~max~ of primary tumor                                                          
  ≤2.3                            1                              1                   
  2.3                             6.08 (3.52--14.65)             3.85 (1.65--8.98)    0.002
  Tumor size (cm)                                                                    
  ≤3                              1                              1                   
  \>3                             1.61 (0.81--3.19)     \<0.001  1.58 (0.75--3.33)    0.225
  Grade                                                                              
  1                               1                      0.175   1                   
  2--4                            1.31 (0.62--2.71)      0.482   1.18 (0.53--2.66)    0.687
  Pleural invasion                                                                   
  Absent                          1                              1                   
  Present                         2.42 (1.06--5.54)      0.037   1.92 (0.73--5.03)    0.182
  Mucinous components                                                                
  Absent                          1                              1                   
  Present                         1.21 (0.71--2.03)      0.487   1.06 (0.62--1.81)    0.817
  *EGFR* mutation                                                                    
  Absent                          1                              1                   
  Present                         1.18 (0.61--2.29)      0.632   1.02 (0.71--1.46)    0.911
  K‐*ras* mutation                                                                   
  Absent                          1                              1                   
  Present                         2.06 (0.49--8.59)      0.321   1.02 (0.56--1.86)    0.959
  Pathological stage                                                                 
  Stage IA                        1                              1                   
  Stage IB                        2.31 (1.19--4.51)      0.014   1.69 (0.82--3.46)    0.153

CEA, carcinoembryonic antigen; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; RFS, recurrence‐free survival; SUV~max~, maximum standardized uptake value.

###### 

Multivariate analyses for RFS and OS in patients with pathological stage I adenocarcinoma

  Variables                   RFS                    OS                        
  --------------------------- -------------------- ------- ------------------- -------
  Age at operation (year)                                                      
  \<70                                                     1                   
  ≥70                         ---                    ---   2.39 (1.09--5.24)    0.029
  Serum CEA (ng/mL)                                                            
  ≤5                          1                            1                   
  \>5                         1.11 (0.53--2.33)     0.776  1.74 (0.79--3.81)    0.163
  SUV~max~ of primary tumor                                                    
  ≤2.3                        1                            1                   
  \>2.3                       5.31 (2.06--13.65)    0.001  3.31 (1.36--8.05)    0.008
  Pleural invasion                                                             
  Absent                      1                                                
  Present                     1.46 (0.57--3.76)     0.429  ---                   ---
  Pathological stage                                                           
  Stage IA                    1                                                
  Stage IB                    1.17 (0.53--2.55)     0.697  ---                   ---

CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; OS, overall survival; RFS, recurrence‐free survival; SUV~max~, maximum standardized uptake value.

Discussion {#tca12428-sec-0017}
==========

We retrospectively evaluated the outcomes of patients with pathological stage I adenocarcinoma. Compared with Western populations, *EGFR* mutations are detected more frequently in the lung adenocarcinomas of Japanese patients, ranging from 40% to 60%.[25](#tca12428-bib-0025){ref-type="ref"}, [26](#tca12428-bib-0026){ref-type="ref"}, [27](#tca12428-bib-0027){ref-type="ref"}, [28](#tca12428-bib-0028){ref-type="ref"}, [29](#tca12428-bib-0029){ref-type="ref"}, [30](#tca12428-bib-0030){ref-type="ref"}, [31](#tca12428-bib-0031){ref-type="ref"} On the other hand, compared with Western populations, K‐*ras* mutations are detected less frequently in the lung adenocarcinomas of Japanese patients.[32](#tca12428-bib-0032){ref-type="ref"} The frequency of K‐*ras* mutation ranges from about from 7% to 16% in worldwide populations.[5](#tca12428-bib-0005){ref-type="ref"}, [30](#tca12428-bib-0030){ref-type="ref"}, [33](#tca12428-bib-0033){ref-type="ref"}, [34](#tca12428-bib-0034){ref-type="ref"} Similarly, the frequency of K‐*ras* mutations was 10.5% in the current study.

The presence of an *EGFR* mutation is closely associated with several clinicopathological features, such as gender and smoking habit. This is consistent with previous studies, which reported that *EGFR* gene mutations are common in lung cancers in never smokers and in women with adenocarcinoma.[6](#tca12428-bib-0006){ref-type="ref"}, [7](#tca12428-bib-0007){ref-type="ref"}, [32](#tca12428-bib-0032){ref-type="ref"} Several reports have described the relationship between K‐*ras* mutation status and clinicopathological features such as gender, smoking habit, and pathological type.[26](#tca12428-bib-0026){ref-type="ref"}, [30](#tca12428-bib-0030){ref-type="ref"}, [35](#tca12428-bib-0035){ref-type="ref"} Similar to results reported in previous studies, the current series showed a relationship between K‐*ras* mutation status and gender. Mucinous bronchioloalveolar carcinoma (BAC)/adenocarcinoma with bronchioloalveolar features is found in 48--76% of adenocarcinomas with K‐*ras* mutations, and K‐*ras* mutations are found in 28--86% of adenocarcinomas with mucinous BAC.[30](#tca12428-bib-0030){ref-type="ref"}, [36](#tca12428-bib-0036){ref-type="ref"}, [37](#tca12428-bib-0037){ref-type="ref"}, [38](#tca12428-bib-0038){ref-type="ref"}, [39](#tca12428-bib-0039){ref-type="ref"}, [40](#tca12428-bib-0040){ref-type="ref"} In the present study, 12 (70.6%) of the 17 cases with K‐*ras* mutations were mucinous BAC/adenocarcinoma with bronchioloalveolar features.

In lung adenocarcinoma simultaneously harboring multiple heterogeneous clones of *EGFR* and K‐*ras* mutations, the effect of *EGFR*‐TKIs may be limited to the parts carrying *EGFR* mutations only.[41](#tca12428-bib-0041){ref-type="ref"}, [42](#tca12428-bib-0042){ref-type="ref"} Because both *EGFR* and K‐*ras* mutations are thought to be early events in lung adenocarcinoma,[32](#tca12428-bib-0032){ref-type="ref"} the reported coexistence of *EGFR* and K‐*ras* mutations only accounts for about 5% of patients with *EGFR* mutations.[43](#tca12428-bib-0043){ref-type="ref"} Takamochi *et al.* reported coexisting *EGFR* and K‐*ras* mutations in two (2%) of 82 patients with lung adenocarcinomas.[6](#tca12428-bib-0006){ref-type="ref"}, [41](#tca12428-bib-0041){ref-type="ref"} A previous study reported that all tumors that had responded to gefitinib had wild type K‐*ras,* [44](#tca12428-bib-0044){ref-type="ref"} thereby suggesting that K‐*ras* and *EGFR* mutations are mutually exclusive.[45](#tca12428-bib-0045){ref-type="ref"} None of the patients in our series had concomitant *EGFR* and K‐*ras* mutations; this result is similar to previous reports, further suggesting that K‐*ras* and *EGFR* mutations are mutually exclusive. Accordingly, combined *EGFR* and K‐*ras* mutation analyses may be helpful in selecting treatment strategies for patients with lung adenocarcinomas.

We also investigated the effects of *EGFR* and K‐*ras* mutation status on survival. Neither *EGFR* nor K‐*ras* mutations affected the prognosis of patients with pathological stage I adenocarcinoma. The prognostic role of *EGFR* mutations in patients with resectable NSCLC has not been established. In their study, Mansuet‐Lupo *et al.* did not find a significant effect on OS for patients with *EGFR* mutations compared with those with wild‐type *EGFR* in their cohort or in a subset with stage I disease.[46](#tca12428-bib-0046){ref-type="ref"} Hu *et al.* found no impact on OS in multivariate analysis when the presence or absence of an *EGFR* mutation was included.[47](#tca12428-bib-0047){ref-type="ref"} On the other hand, in a smaller study, Russell *et al.* conducted molecular analysis and assessed survival outcomes in 59 patients who had undergone surgical resection of lung adenocarcinoma with N2 nodal involvement.[48](#tca12428-bib-0048){ref-type="ref"} Patients with acinar‐predominant adenocarcinoma had significantly better survival than those with micropapillary or solid predominant adenocarcinoma. This trend suggests that patients with resected micropapillary tumors harboring an activating *EGFR* mutation have similar survival outcomes to patients with acinar predominant tumors, whereas patients with micropapillary predominant tumors with wild‐type *EGFR* have poorer outcomes.

Yoshizawa *et al.* did note a statistically and clinically significant improvement in five‐year OS rates in patients with EGFR mutations, but found no difference in five‐year disease‐free survival.[49](#tca12428-bib-0049){ref-type="ref"} However, this result was not included in multivariate analysis in our study.

On the other hand, K‐*ras* mutations have been reported to be prognostic factors in several investigations.[10](#tca12428-bib-0010){ref-type="ref"}, [26](#tca12428-bib-0026){ref-type="ref"}, [32](#tca12428-bib-0032){ref-type="ref"}, [34](#tca12428-bib-0034){ref-type="ref"}, [50](#tca12428-bib-0050){ref-type="ref"} Kosaka *et al.* conducted a prognostic analysis of K‐*ras* mutations in 397 resected adenocarcinomas of Japanese patients and found that patients with K‐*ras* mutations tended to have a shorter survival period.[26](#tca12428-bib-0026){ref-type="ref"} A meta‐analysis of 53 published studies assessing the prognostic value of mutations in the K‐*ras* gene has also been performed.[10](#tca12428-bib-0010){ref-type="ref"} In that analysis, K‐*ras* mutations were identified as a negative prognostic factor in lung adenocarcinoma. Our findings were not consistent with these previous results, and our multivariate analysis revealed that K‐*ras* mutations were not a prognostic factor in patients with resected pathological stage I adenocarcinoma.

Our results suggest that *EGFR* and K‐*ras* gene mutations are not independent prognostic factors in patients with resected pathological stage I adenocarcinoma. Our findings were further analyzed after the data were restricted to patients with pathological stage I disease. Therefore, the analyzed patients were oncologically equivalent, and the analysis regarding the prognostic value of *EGFR* and K‐*ras* gene mutations was valid.

The main limitation of the present study was the retrospective nature of the work. To clarify the true clinicopathological and prognostic features of pathological stage I lung adenocarcinoma harboring *EGFR* and K‐*ras* mutations, prospective or randomized trials are warranted. Furthermore, we elected to exclude patients who had received treatment with neoadjuvant chemotherapy or radiotherapy, as these cases can lead to considerable inaccuracy.

In conclusion, the present study demonstrated that surgically resected pathological stage I adenocarcinoma harboring *EGFR* and K‐*ras* gene mutations has distinct clinicopathological features. The presence of an *EGFR* or a K‐*ras* mutation alone was not a prognostic factor in patients with surgically resected pathological stage I adenocarcinoma.
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